Skip to main content

Table 1 The basic clinical data of enrolled participants

From: Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing

Characteristics

(n [%]or median [IQR])

PJP patients

(N = 33)

Non-PJP patients

(N = 34)

Statistical value

P value

Male

20 (60.61)

24 (70.59)

0.740

0.390

Age (years)

61 (48,67)

61 (50,69)

− 0.217

0.829

Underlying illnesses

Diabetes mellitus

8 (24.24)

7 (20.59)

0.129

0.720

Hypertension

12 (36.36)

12 (35.29)

0.008

0.927

Chronic pulmonary disease

14 (42.42)

7 (20.59)

3.711

0.054

Chronic heart failure

1 (3.03)

1 (2.94)

–

1.000

Immunocompromised conditions

Solid organ transplantation

4 (12.12)

0 (0)

2.490

0.115

Hematologic malignancies

2 (6.06)

2 (5.88)

0.000

1.000

Rheumatic diseases

15 (45.45)

16 (47.06)

0.017

0.895

Solid organ tumors

6 (18.18)

13 (38.24)

3.315

0.069

Glomerulonephritis or nephrotic syndrome

3 (9.09)

2 (5.88)

0.001

0.972

Other types of immunocompromised disease

3 (9.09)

1 (2.94)

0.299

0.585

Use of corticosteroids only

7 (21.21)

3 (9.09)

1.166

0.280

Use of immunosuppressants only

3 (9.09)

3 (9.09)

0.000

1.000

Corticosteroids with immunosuppressants

14 (42.42)

2 (5.88)

12.302

0.000

PJP prophylaxis

1 (3.03)

2 (5.88)

0.000

1.000

  1. PJP Pneumocystis jirovecii Pneumonia